Myeloma management guidelines

A consensus report from the Scientific Advisors of the International Myeloma Foundation

Brian G M Durie, Robert A. Kyle, Andrew Belch, William Bensinger, Joan Blade, Mario Boccadoro, J. Anthony Child, Raymond Comenzo, Ben Djulbegovic, Dorotea Fantl, Gosta Gahrton, Jean Luc Harousseau, Vania Hungria, Douglas Joshua, Heinz Ludwig, Jayesh Mehta, Angelina Rodrique Morales, Gareth Morgan, Amara Nouel, Martin Oken & 9 others Raymond Powles, G. David Roodman, Jesus San Miquel, Kazuyuki Shimizu, Seema Singhal, Bhawna Sirohi, Pieter Sonneveld, Guido Tricot, Brian Van Ness

Research output: Contribution to journalArticle

331 Citations (Scopus)

Abstract

These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including: • A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002). • Review of key literature, especially randomized study results, but also Medline, Internet, Cochrane database searches, and prior guidelines (Br J Haematol 115: 522-540, 2001). • Feedback from patients participating in the International Myeloma Foundation, patient programs. These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. 'Consensus' reflects general, although not necessarily unanimous, agreement. Details are discussed as appropriate. For convenience, the recommendations are divided into: 1 Diagnostic criteria. 2 Staging and prognostic factors. 3 Frontline therapy. 4 High-dose therapy and transplant. 5 Maintenance therapy. 6 Supportive care and management of specific complications. 7 Novel therapies and new technologies.

Original languageEnglish (US)
Pages (from-to)379-398
Number of pages20
JournalHematology Journal
Volume4
Issue number6
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Guidelines
Expert Testimony
Therapeutics
Internet
Databases
Technology
Transplants
Research

Keywords

  • Consensus
  • Guidelines
  • International myeloma foundation
  • Management
  • Multiple myeloma
  • Myeloma

ASJC Scopus subject areas

  • Hematology

Cite this

Durie, B. G. M., Kyle, R. A., Belch, A., Bensinger, W., Blade, J., Boccadoro, M., ... Van Ness, B. (2003). Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematology Journal, 4(6), 379-398. https://doi.org/10.1038/sj.thj.6200312

Myeloma management guidelines : A consensus report from the Scientific Advisors of the International Myeloma Foundation. / Durie, Brian G M; Kyle, Robert A.; Belch, Andrew; Bensinger, William; Blade, Joan; Boccadoro, Mario; Child, J. Anthony; Comenzo, Raymond; Djulbegovic, Ben; Fantl, Dorotea; Gahrton, Gosta; Harousseau, Jean Luc; Hungria, Vania; Joshua, Douglas; Ludwig, Heinz; Mehta, Jayesh; Morales, Angelina Rodrique; Morgan, Gareth; Nouel, Amara; Oken, Martin; Powles, Raymond; Roodman, G. David; San Miquel, Jesus; Shimizu, Kazuyuki; Singhal, Seema; Sirohi, Bhawna; Sonneveld, Pieter; Tricot, Guido; Van Ness, Brian.

In: Hematology Journal, Vol. 4, No. 6, 2003, p. 379-398.

Research output: Contribution to journalArticle

Durie, BGM, Kyle, RA, Belch, A, Bensinger, W, Blade, J, Boccadoro, M, Child, JA, Comenzo, R, Djulbegovic, B, Fantl, D, Gahrton, G, Harousseau, JL, Hungria, V, Joshua, D, Ludwig, H, Mehta, J, Morales, AR, Morgan, G, Nouel, A, Oken, M, Powles, R, Roodman, GD, San Miquel, J, Shimizu, K, Singhal, S, Sirohi, B, Sonneveld, P, Tricot, G & Van Ness, B 2003, 'Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation', Hematology Journal, vol. 4, no. 6, pp. 379-398. https://doi.org/10.1038/sj.thj.6200312
Durie, Brian G M ; Kyle, Robert A. ; Belch, Andrew ; Bensinger, William ; Blade, Joan ; Boccadoro, Mario ; Child, J. Anthony ; Comenzo, Raymond ; Djulbegovic, Ben ; Fantl, Dorotea ; Gahrton, Gosta ; Harousseau, Jean Luc ; Hungria, Vania ; Joshua, Douglas ; Ludwig, Heinz ; Mehta, Jayesh ; Morales, Angelina Rodrique ; Morgan, Gareth ; Nouel, Amara ; Oken, Martin ; Powles, Raymond ; Roodman, G. David ; San Miquel, Jesus ; Shimizu, Kazuyuki ; Singhal, Seema ; Sirohi, Bhawna ; Sonneveld, Pieter ; Tricot, Guido ; Van Ness, Brian. / Myeloma management guidelines : A consensus report from the Scientific Advisors of the International Myeloma Foundation. In: Hematology Journal. 2003 ; Vol. 4, No. 6. pp. 379-398.
@article{bfa834cd93b44c7b80cb5b0c8810c9e9,
title = "Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation",
abstract = "These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including: • A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002). • Review of key literature, especially randomized study results, but also Medline, Internet, Cochrane database searches, and prior guidelines (Br J Haematol 115: 522-540, 2001). • Feedback from patients participating in the International Myeloma Foundation, patient programs. These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. 'Consensus' reflects general, although not necessarily unanimous, agreement. Details are discussed as appropriate. For convenience, the recommendations are divided into: 1 Diagnostic criteria. 2 Staging and prognostic factors. 3 Frontline therapy. 4 High-dose therapy and transplant. 5 Maintenance therapy. 6 Supportive care and management of specific complications. 7 Novel therapies and new technologies.",
keywords = "Consensus, Guidelines, International myeloma foundation, Management, Multiple myeloma, Myeloma",
author = "Durie, {Brian G M} and Kyle, {Robert A.} and Andrew Belch and William Bensinger and Joan Blade and Mario Boccadoro and Child, {J. Anthony} and Raymond Comenzo and Ben Djulbegovic and Dorotea Fantl and Gosta Gahrton and Harousseau, {Jean Luc} and Vania Hungria and Douglas Joshua and Heinz Ludwig and Jayesh Mehta and Morales, {Angelina Rodrique} and Gareth Morgan and Amara Nouel and Martin Oken and Raymond Powles and Roodman, {G. David} and {San Miquel}, Jesus and Kazuyuki Shimizu and Seema Singhal and Bhawna Sirohi and Pieter Sonneveld and Guido Tricot and {Van Ness}, Brian",
year = "2003",
doi = "10.1038/sj.thj.6200312",
language = "English (US)",
volume = "4",
pages = "379--398",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "6",

}

TY - JOUR

T1 - Myeloma management guidelines

T2 - A consensus report from the Scientific Advisors of the International Myeloma Foundation

AU - Durie, Brian G M

AU - Kyle, Robert A.

AU - Belch, Andrew

AU - Bensinger, William

AU - Blade, Joan

AU - Boccadoro, Mario

AU - Child, J. Anthony

AU - Comenzo, Raymond

AU - Djulbegovic, Ben

AU - Fantl, Dorotea

AU - Gahrton, Gosta

AU - Harousseau, Jean Luc

AU - Hungria, Vania

AU - Joshua, Douglas

AU - Ludwig, Heinz

AU - Mehta, Jayesh

AU - Morales, Angelina Rodrique

AU - Morgan, Gareth

AU - Nouel, Amara

AU - Oken, Martin

AU - Powles, Raymond

AU - Roodman, G. David

AU - San Miquel, Jesus

AU - Shimizu, Kazuyuki

AU - Singhal, Seema

AU - Sirohi, Bhawna

AU - Sonneveld, Pieter

AU - Tricot, Guido

AU - Van Ness, Brian

PY - 2003

Y1 - 2003

N2 - These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including: • A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002). • Review of key literature, especially randomized study results, but also Medline, Internet, Cochrane database searches, and prior guidelines (Br J Haematol 115: 522-540, 2001). • Feedback from patients participating in the International Myeloma Foundation, patient programs. These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. 'Consensus' reflects general, although not necessarily unanimous, agreement. Details are discussed as appropriate. For convenience, the recommendations are divided into: 1 Diagnostic criteria. 2 Staging and prognostic factors. 3 Frontline therapy. 4 High-dose therapy and transplant. 5 Maintenance therapy. 6 Supportive care and management of specific complications. 7 Novel therapies and new technologies.

AB - These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including: • A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002). • Review of key literature, especially randomized study results, but also Medline, Internet, Cochrane database searches, and prior guidelines (Br J Haematol 115: 522-540, 2001). • Feedback from patients participating in the International Myeloma Foundation, patient programs. These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. 'Consensus' reflects general, although not necessarily unanimous, agreement. Details are discussed as appropriate. For convenience, the recommendations are divided into: 1 Diagnostic criteria. 2 Staging and prognostic factors. 3 Frontline therapy. 4 High-dose therapy and transplant. 5 Maintenance therapy. 6 Supportive care and management of specific complications. 7 Novel therapies and new technologies.

KW - Consensus

KW - Guidelines

KW - International myeloma foundation

KW - Management

KW - Multiple myeloma

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=9144259158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144259158&partnerID=8YFLogxK

U2 - 10.1038/sj.thj.6200312

DO - 10.1038/sj.thj.6200312

M3 - Article

VL - 4

SP - 379

EP - 398

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -